BIOGEN INC.

- USD (-)

- 15 min delayed data - NASDAQ Stocks

Open:	-
Change:	-
Volume:	-

Low:	-
High:	-
High / Low range:	-

Type:	Stocks
Ticker:	BIIB
ISIN:

BIOGEN INC. overview

> Analyses

Londinia AI has published a new analysis for hsokkar.

0
72339
15104
0

BIOGEN INC. - Daily

Timeframe : Daily - Simple chart
Status : TARGET REACHED

Has the basic bearish trend slowed or is it lacking in power? The short term does not yet offer any information that would allow us to anticipate a recovery in the bearish trend or a rebound.…

Thank you Reply Chart

> Analyses

Londinia AI has published a new analysis for Vincent Launay.

0
72339
15104
0

BIOGEN INC. - Daily

Timeframe : Daily - Simple chart
Status : INVALID

All elements being clearly bearish, it would be possible for traders to trade only short positions (for sale) on BIOGEN INC. as long as the price remains well below 229.90 USD. The sellers” bearish…

Thank you Reply Chart

> Analyses

Londinia AI has published a new analysis for Vincent Launay.

0
72339
15104
0

BIOGEN INC. - Daily

Timeframe : Daily - Simple chart
Status : NEUTRAL

The basic trend is slightly bearish and the short term is tentatively bullish. With such a pattern, it is difficult to favour buying or selling. The first resistance is located at 257.36 USD. The…

Thank you Reply Chart

> News ACCESSWIRE published a news.

Investor Network: Biogen Inc. to Host Earnings Call • • ACCESSWIRE • Stocks • More BIOGEN INC. news...

NEW YORK, NY / ACCESSWIRE / July 25, 2017 / Biogen Inc. (NASDAQ: BIIB ) will be discussing their earnings results in their Q2 Earnings Call to be held on Tuesday, July 25, 2017 at 8:00 AM Eastern Time. To listen to the event live - visit https://www.investornetwork.com/company/23548 . Replay Information The replay will be available online at https://www.investornetwork.com/company/23548 . About Investor Network Investor Network (IN) is a new financial content community, serving millions of...

Thank you Chart

> News CNBC posted a new video.

Red Flag Over Biogen's Expensive Drug For Rare Genetic Disease | Power Lunch | CNBC • • CNBC • Stocks • More BIOGEN INC. news...

CNBC's Meg Tirrell reports that one analyst is raising a red flag on Biogen due to the incredibly high price of a new drug to treat a rare genetic disease in ......

Thank you Chart

> News PR Newswire published a news.

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Biogen Inc. To Contact The Firm Before Imminent Lead Plaintiff Deadline PR Newswire NEW YORK, Dec. 19, 2016 NEW YORK , Dec. 19, 2016 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Biogen Inc. ("Biogen" or the "Company") (NasdaqGS: BIIB) of the December 23, 2016 deadline to seek the role of lead plaintiff in a federal securities...

Thank you Chart

> News PR Newswire published a news.

BIIB INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Shareholders of a Class Action Involving Biogen Inc. and a Lead Plaintiff Deadline of December 23, 2016 • • PR Newswire • Stocks • More BIOGEN INC. news...

BIIB INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Shareholders of a Class Action Involving Biogen Inc. and a Lead Plaintiff Deadline of December 23, 2016 PR Newswire NEW YORK, Nov. 30, 2016 NEW YORK , Nov. 30, 2016 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Biogen Inc. (NASDAQ: BIIB) securities between July 23, 2014 and July 23, 2015 . Click...

Thank you Chart

> News PR Newswire published a news.

Sangamo's Genome Editing Program for Hemoglobinopathies to Transfer to Biogen's Spin-Off Bioverativ • • PR Newswire • Stocks • More BIOGEN INC. news...

Sangamo's Genome Editing Program for Hemoglobinopathies to Transfer to Biogen's Spin-Off Bioverativ ZFN-Mediated Genome Editing Programs in Sickle Cell Disease and Beta-Thalassemia Will Move from Biogen to Bioverativ in Line with the Spin-Off Company's Focus on Rare Blood Disorders PR Newswire RICHMOND, Calif., Nov. 30, 2016 RICHMOND, Calif. , Nov. 30, 2016 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO), a leader in therapeutic genome editing, announced today that its collaborative...

Thank you Chart

Load more content